1. Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer
- Author
-
Luc Ollivier, Maureen Labbé, Delphine Fradin, Vincent Potiron, Stéphane Supiot, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Apoptosis and Tumor Progression (CRCINA-ÉQUIPE 9), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Immunogenic Cell Death and Mesothelioma Therapy (CRCINA-ÉQUIPE 4), Région Pays de Loire : EpiSAVMENLigue Contre le Cancer : Comités 16, 22, 29, 35, 44, 49 and 56Cancéropole Grand Ouest : CGO Structurant 2018 ExomiRTransports LoizeauDe Graet consultingAstra- ZenecaMs. Suzanne Saulnier, Fradin, Delphine, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
- Subjects
Cancer Research ,medicine.medical_treatment ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Review ,Disease ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Immunogenic tumor ,metastasis ,Medicine ,RC254-282 ,radiotherapy ,030304 developmental biology ,0303 health sciences ,business.industry ,treatment combination ,Potent inducer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancer ,Immunotherapy ,prostate cancer ,medicine.disease ,3. Good health ,Radiation therapy ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,immunotherapy ,business - Abstract
International audience; Prostate cancer is the most frequently diagnosed cancer in men and a leading cause of cancer-related death. In recent decades, the development of immunotherapies has resulted in great promise to cure metastatic disease. However, prostate cancer has failed to show any significant response, presumably due to its immunosuppressive microenvironment. There is therefore growing interest in combining immunotherapy with other therapies able to relieve the immunosuppressive microenvironment. Radiation therapy remains the mainstay treatment for prostate cancer patients, is known to exhibit immunomodulatory effects, depending on the dose, and is a potent inducer of immunogenic tumor cell death. Optimal doses of radiotherapy are thus expected to unleash the full potential of immunotherapy, improving primary target destruction with further hope of inducing immune-cell-mediated elimination of metastases at distance from the irradiated site. In this review, we summarize the current knowledge on both the tumor immune microenvironment in prostate cancer and the effects of radiotherapy on it, as well as on the use of immunotherapy. In addition, we discuss the utility to combine immunotherapy and radiotherapy to treat oligometastatic metastatic prostate cancer.
- Published
- 2021
- Full Text
- View/download PDF